Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
or

Resmed Inc (RMD)

Resmed Inc (RMD)
229.00 x 1 234.94 x 2
Post-market by (Cboe BZX)
232.98 -6.50 (-2.71%) 02/14/25 [NYSE]
229.00 x 1 234.94 x 2
Post-market 232.98 unch (unch) 17:01 ET
Quote Overview for Fri, Feb 14th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
232.76
Day High
243.48
Open 241.86
Previous Close 239.48 239.48
Volume 1,025,900 1,025,900
Avg Vol 1,077,505 1,077,505
Stochastic %K 10.53% 10.53%
Weighted Alpha +21.51 +21.51
5-Day Change -3.96 (-1.67%) -3.96 (-1.67%)
52-Week Range 170.56 - 263.05 170.56 - 263.05
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,217,076
  • Shares Outstanding, K 146,867
  • Annual Sales, $ 4,685 M
  • Annual Income, $ 1,021 M
  • EBIT $ 1,605 M
  • EBITDA $ 1,821 M
  • 60-Month Beta 0.70
  • Price/Sales 7.51
  • Price/Cash Flow 25.95
  • Price/Book 6.70

Options Overview Details

View History
  • Implied Volatility 26.44% ( -0.33%)
  • Historical Volatility 33.46%
  • IV Percentile 12%
  • IV Rank 10.77%
  • IV High 63.20% on 08/01/24
  • IV Low 22.00% on 05/09/24
  • Put/Call Vol Ratio 4.89
  • Today's Volume 418
  • Volume Avg (30-Day) 717
  • Put/Call OI Ratio 3.18
  • Today's Open Interest 23,586
  • Open Int (30-Day) 21,916

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.36
  • Number of Estimates 6
  • High Estimate 2.41
  • Low Estimate 2.30
  • Prior Year 2.13
  • Growth Rate Est. (year over year) +10.80%

Price Performance

See More
Period Period Low Period High Performance
1-Month
229.09 +1.70%
on 01/15/25
Period Open: 228.83
263.05 -11.43%
on 01/30/25
+4.15 (+1.81%)
since 01/14/25
3-Month
224.51 +3.77%
on 12/23/24
Period Open: 231.43
263.05 -11.43%
on 01/30/25
+1.55 (+0.67%)
since 11/14/24
52-Week
170.56 +36.60%
on 03/01/24
Period Open: 180.55
263.05 -11.43%
on 01/30/25
+52.43 (+29.04%)
since 02/14/24

Most Recent Stories

More News
DVA Stock Down in Pre-Market Despite Q4 Earnings Beat, Margins Expand

DaVita Inc. DVA delivered adjusted earnings per share (EPS) of $2.24 in the fourth quarter of 2024, up 19.8% year over year. The figure surpassed the Zacks Consensus Estimate by 1.4%.Find the latest EPS...

BSX : 106.11 (-0.03%)
RMD : 232.98 (-2.71%)
CAH : 126.21 (-0.45%)
DVA : 157.42 (-11.09%)
WST Stock Declines in Pre-Market Despite Q4 Earnings Beat, Margins Down

West Pharmaceutical Services, Inc. WST delivered adjusted earnings per share (EPS) of $1.82 in the fourth quarter of 2024, down by a penny year over year. The figure topped the Zacks Consensus Estimate...

BSX : 106.11 (-0.03%)
RMD : 232.98 (-2.71%)
WST : 214.73 (+7.84%)
CAH : 126.21 (-0.45%)
EW Stock Up on Q4 Earnings and Revenue Beat, Margins Crash

Edwards Lifesciences Corporation EW reported fourth-quarter 2024 adjusted earnings per share (EPS) of 59 cents, which surpassed the Zacks Consensus Estimate by 7.3%. The figure increased 7.3% from the...

EW : 76.19 (+0.25%)
DGX : 168.77 (+0.03%)
RMD : 232.98 (-2.71%)
CAH : 126.21 (-0.45%)
DexCom (DXCM) To Report Earnings Tomorrow: Here Is What To Expect

DexCom (DXCM) To Report Earnings Tomorrow: Here Is What To Expect

RMD : 232.98 (-2.71%)
ISRG : 595.55 (+0.70%)
DXCM : 89.07 (+5.92%)
ECL Stock Up in Pre-Market Following Q4 Earnings Beat, Margins Expand

Ecolab Inc. ECL reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.81, up 16.8% year over year. The bottom line exceeded the Zacks Consensus Estimate by 1.1%.Find the latest EPS estimates...

BSX : 106.11 (-0.03%)
RMD : 232.98 (-2.71%)
CAH : 126.21 (-0.45%)
ECL : 264.74 (-0.27%)
ILMN Q4 Earnings Miss Estimates, Stock Dips in Aftermarket

Illumina Inc. ILMN reported fourth-quarter 2024 adjusted earnings per share (EPS) of 86 cents, which missed the Zacks Consensus Estimate of 92 cents by 6.5%. The bottom line was significantly above the...

DGX : 168.77 (+0.03%)
ILMN : 100.24 (-1.51%)
RMD : 232.98 (-2.71%)
CAH : 126.21 (-0.45%)
ZBH's Q4 Earnings Beat, Margins Contract, Stock Down in Premarket

Zimmer Biomet Holdings, Inc. ZBH posted fourth-quarter 2024 adjusted earnings per share (EPS) of $2.31, beating the Zacks Consensus Estimate by a penny. The adjusted figure increased 5% year over year.See...

ZBH : 100.52 (+0.61%)
DGX : 168.77 (+0.03%)
RMD : 232.98 (-2.71%)
CAH : 126.21 (-0.45%)
STE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket

STERIS plc STE reported third-quarter fiscal 2025 adjusted earnings per share (EPS) of $2.32, up 9.9% from the year-ago quarter’s figure. The figure is in line with the Zacks Consensus Estimate. Find...

DGX : 168.77 (+0.03%)
STE : 219.34 (+0.05%)
RMD : 232.98 (-2.71%)
CAH : 126.21 (-0.45%)
ALGN Q4 Earnings Top Estimates, Revenues Miss, Stock Falls

Align Technology, Inc. ALGN delivered fourth-quarter 2024 adjusted earnings per share (EPS) of $2.44, up 0.8% from the year-ago level. The reported figure topped the Zacks Consensus Estimate by 0.4%.Find...

DGX : 168.77 (+0.03%)
RMD : 232.98 (-2.71%)
CAH : 126.21 (-0.45%)
ALGN : 206.77 (+0.92%)
Bio-Techne Tops Q2 Earnings & Revenue Estimates, Stock Up in Premarket

Bio-Techne TECH reported second-quarter fiscal 2025 adjusted earnings per share (EPS) of 42 cents, which exceeded the Zacks Consensus Estimate by 10.5%. The bottom line improved from the year-ago figure...

TECH : 65.94 (-1.24%)
DGX : 168.77 (+0.03%)
RMD : 232.98 (-2.71%)
CAH : 126.21 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory...

See More

Key Turning Points

3rd Resistance Point 250.77
2nd Resistance Point 247.12
1st Resistance Point 240.05
Last Price 232.98
1st Support Level 229.33
2nd Support Level 225.69
3rd Support Level 218.62

See More

52-Week High 263.05
Last Price 232.98
Fibonacci 61.8% 227.72
Fibonacci 50% 216.80
Fibonacci 38.2% 205.89
52-Week Low 170.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Increase Profitable Opportunities with Barchart's Technical Opinion